X

Trial Profile

A phase III pivotal study of ADP101 in Food-hypersensitivity

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADP 101 (Primary)
Indications Food hypersensitivity
Focus Registrational; Therapeutic Use
Sponsors Alladapt Immunotherapeutics

Most Recent Events

13 Jun 2023 According to an Alladapt Immunotherapeutics media release, the company anticipates initiation of the Phase 3 program focused on the pediatric population in 2024.
01 Sep 2022 New trial record
30 Aug 2022 According to an Alladapt Immunotherapeutics, the company has entered in to a term loan agreement for up to $50 million with Hercules Capital which will be used to fund this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com